“We are addressing one of humanity’s urgent need: a quick access to highly versatile and efficient vaccines”
Christophe Hubert, President CEO of LinKinVax
LinkinVax’s ambition is to disrupt vaccine development using a unique dendritic cell-targeting vaccine platform.
Existing vaccines technologies prove to be efficient but slow to develop needing to start over for every new disease or even variant.
In a world facing fast evolving pathogens and growing risks of recurring epidemic outbreaks, we need a faster, more agile, alternative.
LinKinVax aims at creating a universal, safe, enduring, vaccines platform allowing the fast development of a wide range of vaccines against multiple pathogens.
“Bringing the right antigen to the right activated cell, our solution generates a wide range of novel DC-based vaccines candidates, both preventive and therapeutic”
Pr. Yves Lévy, Chief Medical & Scientific Officer, Founder
Based on a Nobel Prize winning discovery, the vaccines platform is a proven, easy to produce, monoclonal antibody targeting dendritic cells to trigger an immune response. It addresses specific pathogens through antigens modulation.
Combination of a fixed vessel and a modulated antigen significantly hastens the development of a vaccine for new or mutated pathogens.
Four clinical trials of novel vaccines are already planned: two against HIV – a preventive and a therapeutic one – one against HPV linked cancer and another one against SARS-CoV-2.
“As a biotech startup fast-tracking vaccine development from basic science to market, LinKinvax unites the best of both worlds.”
Christophe Hubert, President CEO of LinKinVax
LinKinVax is at the crossroads of two worlds where Moore’s law meets biotechnology to bring breakthrough innovations to the market.
A unique network of public and private partners
LinKinVax operates within a stable network of leading scientific institutions, pharmaceutical companies and university hospitals.
With a binding contract with the French National Institute of Health and Medical Research (Inserm) as institutional coordinator and the Vaccine Research Institute (VRI) as scientific leader, LinKinVax secured access to a unique patent portfolio; an international network of clinical facilities; and world leading industrial subcontractors.
LinKinVax operates within a stable network of leading scientific institutions, pharmaceutical companies and university hospitals.
With a binding contract with the French National Institute of Health and Medical Research (Inserm) as institutional coordinator and the Vaccine Research Institute (VRI) as scientific leader, LinKinVax secured access to a unique patent portfolio; an international network of clinical facilities; and world leading industrial subcontractors.
“We cannot pretend to protect life if we harm it in any other way. LinKinVax’s approach of ethics is strong and simple : do the right thing.”
Christophe Hubert, President CEO of LinKinVax
Along with our partners, we are committed to the highest standards of compliance, openness and responsibility regarding the way we conduct biological and medical research.
Clinical research involving animal and human subjects remain critical in developing new vaccines. We chose to go beyond respecting international, European and French legal rules to submit every research project to the French National Institute of Health and Medical Research (INSERM)’s Ethic Committee before going ahead.
Every step of our research program is conducted following good practice and regulatory standards ensuring scientific integrity and patient safety.
As a data intensive activity, our research also follows an ethical approach to the treatment and protection of personal information. We take pride in knowing that any person participating in our research fully understands her contribution to the greater good and the process involved.
Detailing our methods and publishing our work is key to remain accountable for every part of our activity.
Besides research ethics, we are also committed to building a sustainable, inclusive and emancipating company.
Dendritic cells Discovery by Ralph Steinman
Nobel Prize in Physiology or Medicine for the discovery of the dendritic cell and its role in adaptative immunity by Ralph Steinman, Bruce Beutler and Jules Hoffmann
Creation of the Vaccine Research Institute (VRI) on dendritic cell-targeting vaccines by Yves Lévy
Discovery of a second-generation vaccine against SARS-CoV-2
Creation of biotech start-up Linkinvax by André-Jacques Auberton, Yves Lévy and Rémy Gaston-Dreyfus
SARS-CoV-2, HIV and HPV linked cancer vaccines going through clinical trial
November 2023: Appointment of a new president CEO, Christophe Hubert